retatrutide research study The Effect of on Kidney Parameters in Participants With Type 2 Diabetes Mellitus and/or Obesity Retatrutide—A Game Changer in Obesity

Description

#TaibaRare #RareMetabolicDisease #PatientAwareness #LipodystrophyAwareness #RareDisease #MetabolicHealth #WorldLipodystrophyDay #RareDisorders #ChronicIllness To view or add a comment, sign in Ashley Shoemaker, MD, MSci, of Vanderbilt Health discusses the FDA approval of setmelanotide (Imcivree), the first targeted therapy for acquired hypothalamic obesity in patients 4+ years

To date there have been no systematic reviews on the safety of GLP-1 agonists and/or SGLT2 inhibitors during pregnancy or lactation

however, randomized controlled trials and a large international cohort study have shown no increases in thyroid cancer risk in humans.[7779] Isolated study findings have also raised concerns about ocular adverse events, including retinopathy and non-arthritic anterior ischemic optic neuropathy (NAION).[11, 80] However, to date, meta-analyses have failed to find associations between GLP-1RAs and NAION, and only albiglutide, a GLP-1RA discontinued in 2017, has been associated with an increased risk of retinopathy.[80, 81] In adults 66 years and older with diabetes, a cohort study found a two-fold increase in risk for neovascular age-related macular degeneration in those using GLP-1RAs for one year or more.[82] Accessibility Despite the expanding indications and potential therapeutic benefits of GLP-1RAs, disparities in cost-related access may hinder their utilization in populations that stand to benefit the most.[83] In the U.S., individuals identifying as Hispanic and non-Hispanic Blackgroups with higher obesity prevalencedemonstrate significantly lower initiation rates of GLP-1RAs compared to individuals identifying as White.[83, 84] Additionally, individuals enrolled in Medicaid, Medicare, or lacking insurance are less likely to initiate GLP-1RA therapy relative to those with private insurance coverage